CIA
APLS

Capital Impact Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Capital Impact Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,574
Closed -$508K – 113
2023
Q2 		$508K Sell
5,574
-8,360
-60% -$721K 0.56% 83
2023
Q1 		$919K Sell
13,934
-25
-0.2% -$1.44K 1.13% 9
2022
Q4 		$722K Hold
13,959
– – 0.71% 41
2022
Q3 		$604K Buy
13,959
+659
+5% +$39K 0.6% 51
2022
Q2 		$601K Buy
+13,300
New +$606K 0.56% 66

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Impact Advisors's APLS Position: Q3 2023 in Review

Capital Impact Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 5,574 shares — an estimated $508K sold.

Capital Impact Advisors first reported a position in APLS in Q2 2022 and held it in 5 quarters. The position peaked at $919K in Q1 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Capital Impact Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Capital Impact Advisors sold 5,574 Apellis Pharmaceuticals shares in Q3 2023, an estimated $508K.
  • Capital Impact Advisors first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Capital Impact Advisors's Apellis Pharmaceuticals position peaked at $919K in Q1 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.